BLOOD RESEARCH

The Korean Society of Hematology (대한혈액학회)
권호 표지
DOI QR코드

DOI QR Code

Treatment and clinical outcomes of patients relapsing after allogeneic hematopoietic cell transplantation for myelodysplastic syndrome

  • Choi, Eun-Ji (Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lee, Je-Hwan (Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lee, Jung-Hee (Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Park, Han-Seung (Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Ko, Sun-Hye (Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Seol, Miee (Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lee, Young-Shin (Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kang, Young-Ah (Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Jeon, Mijin (Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lee, Kyoo-Hyung (Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine)
  • Received : 2018.06.05
  • Accepted : 2018.06.28
  • Published : 2018.12.31
⟨ Previous Next ⟩

Abstract

Background Although allogeneic hematopoietic cell transplantation (HCT) is the only curative treatment option for myelodysplastic syndrome (MDS), a substantial number of patients experience relapse. We reviewed the clinical outcomes of patients with MDS who relapsed after allogeneic HCT. Methods Thirty patients who experienced relapse or progression after allogeneic HCT for MDS between July 2000 and May 2016 were included in this retrospective analysis. Results The median time from HCT to relapse was 6.6 (range, 0.9-136.3) months. Donor lymphocyte infusions (DLIs) were administered to four patients: one achieved complete remission (CR) and survived disease free, while three did not respond to DLI and died. Hypomethylating agents were administered to seven patients: one who had stable disease continuously received decitabine, while six died without response to treatment. Six patients received AML-like intensive chemotherapy, and three achieved CR: two underwent second HCT and one DLI. One patient receiving second HCT survived without disease, but the other two relapsed and died. Three, four, and eight patients who did not respond to intensive chemotherapy, low-dose cytarabine, and best supportive care, respectively, died. One patient who underwent second HCT following cytogenetic relapse survived disease free. Median overall survival after relapse was 4.4 months, and relapse within 6 months after HCT was associated with shorter survival. Conclusion Outcomes of MDS patients relapsing after allogeneic HCT were disappointing. Some patients could be saved using DLI or second HCT.

Keywords

References

  1. Thanarajasingam G, Kim HT, Cutler C, et al. Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013;19:1713-8. https://doi.org/10.1016/j.bbmt.2013.09.011
  2. Kekre N, Koreth J. Novel strategies to prevent relapse after allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes. Curr Opin Hematol 2015;22:116-22. https://doi.org/10.1097/MOH.0000000000000116
  3. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419-25. https://doi.org/10.1182/blood-2005-10-4149
  4. Guieze R, Damaj G, Pereira B, et al. Management of myelodysplastic syndrome relapsing after allogeneic hematopoietic stem cell transplantation: a study by the French Society of Bone Marrow Transplantation and Cell Therapies. Biol Blood Marrow Transplant 2016;22:240-7. https://doi.org/10.1016/j.bbmt.2015.07.037
  5. Sauer T, Silling G, Groth C, et al. Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT. Bone Marrow Transplant 2015;50:485-92. https://doi.org/10.1038/bmt.2014.300
  6. Schroeder T, Czibere A, Platzbecker U, et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia 2013;27:1229-35. https://doi.org/10.1038/leu.2013.7
  7. Orti G, Sanz J, Bermudez A, et al. Outcome of second allogeneic hematopoietic cell transplantation after relapse of myeloid malignancies following allogeneic hematopoietic cell transplantation: A Retrospective Cohort on Behalf of the Grupo Espanol de Trasplante Hematopoyetico. Biol Blood Marrow Transplant 2016;22:584-8. https://doi.org/10.1016/j.bbmt.2015.11.012
  8. Takami A, Yano S, Yokoyama H, et al. Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2014;20:1785-90. https://doi.org/10.1016/j.bbmt.2014.07.010
  9. Krishnamurthy P, Potter VT, Barber LD, et al. Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant 2013;19:562-8. https://doi.org/10.1016/j.bbmt.2012.12.013
  10. Oran B, Giralt S, Couriel D, et al. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia 2007;21:2540-4. https://doi.org/10.1038/sj.leu.2404828
  11. Platzbecker U, Wermke M, Radke J, et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 2012;26:381-9. https://doi.org/10.1038/leu.2011.234

Cited by

  1. Allogeneic hematopoietic stem cell transplantation from a 2-HLA-haplotype-mismatched family donor for posttransplant relapse: a prospective phase I/II study vol.56, pp.1, 2018, https://doi.org/10.1038/s41409-020-0980-8
  2. Diagnosis and therapeutic decision-making for the neutropenic patient vol.2021, pp.1, 2021, https://doi.org/10.1182/hematology.2021000284